Rhumbline Advisers Bio Atla, Inc. Transaction History

Rhumbline Advisers

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.37 - $3.92 $58,422 - $167,164	-42,644 Reduced 67.91%	20,151 $27,000
Q1 2024 May 09, 2024	BUY	$1.88 - $3.46 $3,963 - $7,293	2,108 Added 3.47%	62,795 $216,000
Q4 2023 Feb 08, 2024	SELL	$1.27 - $3.18 $2,114 - $5,294	-1,665 Reduced 2.67%	60,687 $149,000
Q3 2023 Nov 09, 2023	BUY	$1.7 - $3.07 $6,164 - $11,131	3,626 Added 6.17%	62,352 $105,000
Q2 2023 Aug 08, 2023	BUY	$2.83 - $3.87 $166,194 - $227,269	58,726 New	58,726 $176,000
Q2 2022 Aug 11, 2022	SELL	$2.13 - $5.38 $30,989 - $78,273	-14,549 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.38 - $18.78 $10,231 - $43,870	2,336 Added 19.13%	14,549 $73,000
Q4 2021 Feb 10, 2022	BUY	$19.0 - $30.95 $16,834 - $27,421	886 Added 7.82%	12,213 $240,000
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $24,523 - $36,435	833 Added 7.94%	11,327 $333,000
Q2 2021 Aug 05, 2021	SELL	$38.07 - $56.17 $11,344 - $16,738	-298 Reduced 2.76%	10,494 $445,000
Q1 2021 May 06, 2021	BUY	$32.41 - $70.91 $349,768 - $765,260	10,792 New	10,792 $549,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.